Stock PRFX PAINREFORM LTD.
Add to a list
To use this feature you must be a member
Log inSign up

PainReform Ltd. Stock

Equities

PRFX

IL0011651580

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
0.71 USD -.--% Intraday chart for PainReform Ltd. +1.43% -74.18%
May. 15 PainReform Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 16 PainReform Prices $4 Million Offering; Shares Tumble Pre-Bell MT

Financials (USD)

Sales 2024 * - Sales 2025 * - Capitalization 1.76M
Net income 2024 * -22M Net income 2025 * -26M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-0.2 x
P/E ratio 2025 *
-0.35 x
Employees 7
Yield 2024 *
-
Yield 2025 *
-
Free-Float 77.87%
More Fundamentals * Assessed data

Chart PainReform Ltd.

Dynamic Chart

Latest news about PainReform Ltd.

PainReform Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
PainReform Prices $4 Million Offering; Shares Tumble Pre-Bell MT
Painreform Ltd. Announces Groundbreaking Results from New Studies Demonstrating the Superior In-Vitro Release Rates of PRF-110 CI
PainReform Ltd. Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy CI
PainReform Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief CI
PainReform Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Certain Warrants of PainReform Ltd. are subject to a Lock-Up Agreement Ending on 17-OCT-2023. CI
Certain Ordinary Shares of PainReform Ltd. are subject to a Lock-Up Agreement Ending on 17-OCT-2023. CI
PainReform Ltd. Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File CI
PainReform Ltd. Announces Selection for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary CI
PainReform Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Top Premarket Gainers MT
PainReform Regains Compliance With Nasdaq Listing Rule MT
Sector Update: Health Care Stocks Advancing Late Friday MT
More news

Press releases PainReform Ltd.

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification AQ
PAINREFORM : CONDENSED FINANCIAL STATEMENTS - Form 6-K PU
PainReform Provides Business Update for the First Quarter of 2024 AQ
PainReform : CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com PU
PainReform Announces Closing of $4 Million Public Offering AQ
More press releases

Quotes and Performance

1 week+1.43%
1 month-23.12%
3 months-62.63%
6 months-71.60%
Current year-74.18%
More quotes

Highs and lows

1 week
0.67
Extreme 0.67
0.75
1 month
0.65
Extreme 0.65
0.97
Current year
0.65
Extreme 0.65
2.98
1 year
0.65
Extreme 0.65
26.41
3 years
0.65
Extreme 0.65
78.40
5 years
0.65
Extreme 0.65
78.50
10 years
0.65
Extreme 0.65
78.50
More quotes

Managers and Directors - PainReform Ltd.

Managers TitleAgeSince
Ilan Hadar CEO
 Chief Executive Officer 55 20-11-22
Ehud Geller CHM
 Chairman 77 08-10-31
Sigal Aviel COO
 Chief Operating Officer 60 -
Members of the board TitleAgeSince
Augustine Lawlor BRD
 Director/Board Member 67 20-08-31
Ellen Baron BRD
 Director/Board Member 71 20-08-31
Ehud Geller CHM
 Chairman 77 08-10-31
More insiders

Quotes

Date Price Change Volume
24-05-31 0.71 -.--% 12,275
24-05-30 0.71 +1.43% 8,474
24-05-29 0.7 +1.82% 34,213
24-05-28 0.6875 -1.79% 17,257
24-05-24 0.7 -3.88% 60,027

Delayed Quote Nasdaq, May 31, 2024 at 04:30 pm EDT

More quotes

Company Profile

PAINREFORM LTD is a Israel-based pharmaceutical Company. The Company’s main activity is to develop reformulation of established pain therapeutics. PainReform Ltd provides technology, which is dedicated to prolong and enhance efficacy, minimize adverse effects and increase patients convenience as well as faster return of motor function.
Sector
Pharmaceuticals
Calendar
2024-08-12 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.71 USD
Average target price
2 USD
Spread / Average Target
+181.69%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
PAINREFORM LTD. Stock PainReform Ltd.
-74.18% 1.76M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
NOVARTIS AG Stock Novartis AG
+9.78% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PRFX Stock